Effective: 1/1/2025 Last Revision: 8/20/2024 Last Clinical Review: 8/1/2024

LUNG CANCER FOCUSED PANEL TESTS VIA CIRCULATING TUMOR DNA (CTDNA)

- Lung cancer focused panel tests via circulating tumor DNA (ctDNA) (0179U, 0388U, 81210, 81235, 81275, 81462, 81479) are considered **medically necessary** when:
 - A. The member has a diagnosis or progression of any of the following:
 - 1. Advanced or metastatic lung adenocarcinoma, **OR**
 - 2. Advanced or metastatic large cell lung carcinoma, OR
 - 3. Advanced or metastatic squamous cell lung carcinoma, OR
 - 4. Advanced or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS).
- II. Lung cancer focused panel tests via circulating tumor DNA (ctDNA) (0179U, 0388U, 81210, 81235, 81275, 81462, 81479) are considered **investigational** for all other indications.

DEFINITIONS

 Circulating tumor DNA (ctDNA): Fragmented, tumor-derived DNA circulating in the bloodstream that is not being carried in a cell. ctDNA derives either directly from the tumor or from circulating tumor cells.



Effective: 1/1/2025 Last Revision: 8/20/2024 Last Clinical Review: 8/1/2024

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

